Identification of possible drug treatment targets and related immune cell infiltration properties in acute myeloid leukemia utilizing robust rank aggregation algorithm.

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia & Lymphoma Pub Date : 2025-01-15 DOI:10.1080/10428194.2025.2451064

Hengzhou Zhu, Chencen Zhang, Lei Huang, Baonan Zhang, Xiaona Huang, Jianliang You, Chunhui Jin

{"title":"Identification of possible drug treatment targets and related immune cell infiltration properties in acute myeloid leukemia utilizing robust rank aggregation algorithm.","authors":"Hengzhou Zhu, Chencen Zhang, Lei Huang, Baonan Zhang, Xiaona Huang, Jianliang You, Chunhui Jin","doi":"10.1080/10428194.2025.2451064","DOIUrl":null,"url":null,"abstract":"<p><p>In this study, we aimed to uncover novel biomarkers in acute myeloid leukemia (AML) that could serve as prognostic indicators or therapeutic targets. We analyzed AML microarray datasets from the Gene Expression Omnibus (GEO) repository, identifying key differentially expressed genes (DEGs) through the robust rank aggregation (RRA) approach. The functions of these DEGs were elucidated through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Additionally, the CIBERSORT algorithm was employed to assess immune cell infiltration in AML. Six hub genes were identified using the cytoHubba plugin, and their clinical significance, survival impact, and meta-analyses were conducted. Through comprehensive bioinformatics and qPCR analyses, we gained new insights into AML pathogenesis and metastasis, identifying FCGR3B, FLT3, EREG, and MMP9 as potential prognostic biomarkers. Antagonists targeting FCGR3B, FLT3, and MMP9, or agonists for EREG, hold promise as therapeutic and preventative strategies for AML.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.2000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2025.2451064","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

In this study, we aimed to uncover novel biomarkers in acute myeloid leukemia (AML) that could serve as prognostic indicators or therapeutic targets. We analyzed AML microarray datasets from the Gene Expression Omnibus (GEO) repository, identifying key differentially expressed genes (DEGs) through the robust rank aggregation (RRA) approach. The functions of these DEGs were elucidated through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Additionally, the CIBERSORT algorithm was employed to assess immune cell infiltration in AML. Six hub genes were identified using the cytoHubba plugin, and their clinical significance, survival impact, and meta-analyses were conducted. Through comprehensive bioinformatics and qPCR analyses, we gained new insights into AML pathogenesis and metastasis, identifying FCGR3B, FLT3, EREG, and MMP9 as potential prognostic biomarkers. Antagonists targeting FCGR3B, FLT3, and MMP9, or agonists for EREG, hold promise as therapeutic and preventative strategies for AML.

查看原文本刊更多论文

利用鲁棒秩聚集算法识别急性髓系白血病可能的药物治疗靶点和相关免疫细胞浸润特性

在这项研究中，我们旨在发现急性髓性白血病（AML）中可以作为预后指标或治疗靶点的新的生物标志物。我们分析了来自基因表达综合库（Gene Expression Omnibus， GEO）的AML微阵列数据集，通过鲁棒秩聚合（robust rank aggregation， RRA）方法识别关键差异表达基因（deg）。通过基因本体（GO）和京都基因与基因组百科全书（KEGG）富集分析，阐明了这些基因的功能。此外，采用CIBERSORT算法评估AML中的免疫细胞浸润。使用cytoHubba插件鉴定了6个枢纽基因，并进行了临床意义、生存影响和荟萃分析。通过综合生物信息学和qPCR分析，我们对AML的发病机制和转移有了新的认识，确定了FCGR3B、FLT3、EREG和MMP9作为潜在的预后生物标志物。靶向FCGR3B、FLT3和MMP9的拮抗剂或EREG激动剂有望成为AML的治疗和预防策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Leukemia & Lymphoma 医学-血液学

CiteScore

4.10

自引率

3.80%

发文量

384

审稿时长

1.8 months

期刊介绍： Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor